Long-term Follow-up of Subfoveal Neovascular AMD

NCT ID: NCT01608113

Last Updated: 2012-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatment naive patients with subfoveal nAMD initially treated monthly with intravitreal anti-VEGF and subsequently PRN, will be included in this study. Patients will be investigated for the first 2 years monthly and subsequently according to disease activity but at least every two months. Patients will be examined with 4m BCVA ETDRS distance visual acuity, reading acuity measured by Radner-Reading-Charts, contrast sensitivity by Pelli-Robson score, microperimetry and HD-OCT.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Exudative Age-related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* treatment naive subfoveal AMD, written informed consent, able to read

Exclusion Criteria

* choroidal neovascularisation due to other ocular diseases, mature cataract
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Vienna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christopher Kiss

Head of Vienna Study Center

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christopher G Kiss, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Ophthalmology Medical University of Vienna

Vienna, Vienna, Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jasmin Mittermüller

Role: primary

00431404004847

Germana Armberger

Role: backup

00431404004847

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EK 802/2011

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
NCT03999801 ENROLLING_BY_INVITATION PHASE2